MedTrace Logo

Precedex Versus Propofol-Awakening for Reducing Brain Injury Expansion

NCT00538616 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2013-04-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate brain injury when two different drugs (propofol and precedex) are used to sedate patients who need a neurologic exam.

Conditions

  • Brain Injury
  • Intracranial Pressure

Interventions

DRUG

Dexmedetomidine

in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)

DRUG

Propofol

in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)

Sponsors & Collaborators

  • Hospira, now a wholly owned subsidiary of Pfizer

    collaborator INDUSTRY

  • Carmelo Graffagnino

    lead OTHER

Principal Investigators

  • Carmelo Graffagnino, MD · Duke University

  • DaiWai M Olson, PhD RN · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2008-02-29
Completion
2010-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00538616 on ClinicalTrials.gov